Literature DB >> 21107607

The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis.

Yu Yang1, Chao Luo, R Feng, Sheng Bi.   

Abstract

OBJECTIVE: TNF-α-308 G/A, TNF-α-238 G/A, IL-1B-31 T/C, IL-1B-511 C/T, and IL-10-1082 G/A polymorphisms have been reported to influence the risk for hepatocellular carcinoma (HCC) in many studies; however, the results still remains controversial and ambiguous. The aim of this study was to determine more precise estimations for the relationship between TNF-α, IL-1B, and IL-10 polymorphisms and the risk for HCC by meta-analysis.
METHODS: Electronic searches for all publications were conducted on associations between these variants and HCC in several databases through September 2010. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated to estimate the strength of this association in a random-effect model. Twenty studies were identified, involving 2,763 HCC patients and 4,152 controls.
RESULTS: This meta-analysis showed significant association between TNF-α-308 polymorphism and HCC (AA + GA vs. GG: OR = 1.74, 95% CI = 1.12-2.72). In Caucasian and Asian subgroups, OR values (95% CI) were 1.49 (0.58-3.82) and 1.84 (1.06-3.20), respectively. While the ORs for TNF-α-238 G/A, IL-1B-31 T/C, -511 C/T and IL-10-1082 G/A polymorphisms and HCC were 1.37 (0.95-2.00), 1.24 (0.99-1.55), 1.12 (0.66-1.88) and 0.91 (0.74-1.12), respectively. The sensitivity analysis further strengthened the overall strong positive correlations. No publication bias was observed in this study.
CONCLUSIONS: TNF-α-308 G/A polymorphism is assumed to confer a higher risk for HCC, especially in Asian population. TNF-α-238 G/A, IL-1B-31 T/C, -511 C/T, and IL-10-1082 G/A polymorphisms were not detected to be related to the risk for HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107607     DOI: 10.1007/s00432-010-0959-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma.

Authors:  Stephan Hellmig; Wolfgang Fischbach; Maria-Elisabeth Goebeler-Kolve; Ulrich Robert Fölsch; Jochen Hampe; Stefan Schreiber
Journal:  Am J Gastroenterol       Date:  2005-12       Impact factor: 10.864

2.  TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.

Authors:  T W Huizinga; R G Westendorp; E L Bollen; V Keijsers; B M Brinkman; J A Langermans; F C Breedveld; C L Verweij; L van de Gaer; L Dams; J B Crusius; A García-Gonzalez; B W van Oosten; C H Polman; A S Peña
Journal:  J Neuroimmunol       Date:  1997-02       Impact factor: 3.478

3.  Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection.

Authors:  Grazia Anna Niro; Rosanna Fontana; Domenica Gioffreda; Maria Rosa Valvano; Angelo Lacobellis; Domenico Facciorusso; Angelo Andriulli
Journal:  Liver Int       Date:  2005-12       Impact factor: 5.828

4.  Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association.

Authors:  Alexandra Nieters; Jian-Min Yuan; Can-Lan Sun; Zhen-Quan Zhang; Jan Stoehlmacher; Sugantha Govindarajan; Mimi C Yu
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

Review 5.  Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.

Authors:  G Mark Anderson; Marian T Nakada; Mark DeWitte
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

6.  Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population.

Authors:  P Kummee; P Tangkijvanich; Y Poovorawan; N Hirankarn
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

7.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity.

Authors:  Nadia Bouzgarrou; Elham Hassen; Karim Farhat; Olfa Bahri; Sallouha Gabbouj; Nadia Maamouri; Nabil Ben Mami; Hammouda Saffar; Abdelhalim Trabelsi; Henda Triki; Lotfi Chouchane
Journal:  Hum Immunol       Date:  2009-01-29       Impact factor: 2.850

10.  Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Huey-Ru Tsai; Lee-Yea Chuang; Jung-Fa Tsai; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Medicine (Baltimore)       Date:  2009-11       Impact factor: 1.889

View more
  29 in total

Review 1.  Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Authors:  Pierre Nahon; Angela Sutton; Marianne Ziol; Jessica Zucman-Rossi; Jean-Claude Trinchet; Nathalie Ganne-Carrié
Journal:  Hepat Oncol       Date:  2015-01-12

Review 2.  Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis.

Authors:  Yonggang Wei; Fei Liu; Bo Li; Xi Chen; Yu Ma; Lvnan Yan; Tianfu Wen; Mingqing Xu; Wentao Wang; Jiayin Yang
Journal:  Dig Dis Sci       Date:  2011-02-19       Impact factor: 3.199

3.  Human genetic variation and the risk of hepatocellular carcinoma development.

Authors:  Sayeh Ezzikouri; Soumaya Benjelloun; Pascal Pineau
Journal:  Hepatol Int       Date:  2013-08-02       Impact factor: 6.047

4.  Inhibitory effects of simvastatin on staphylococcus aureus lipoteichoic acid-induced inflammation in human alveolar macrophages.

Authors:  Ben-Quan Wu; Jin-Mei Luo; Yan-Hong Wang; Yun-Feng Shi; Hui Liu; Jun-Hui Ba; Tian-Tuo Zhang
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984

5.  A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer.

Authors:  Hua-Lian Zhang; Yi-Jie Zhang
Journal:  Tumour Biol       Date:  2013-03-15

6.  Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis.

Authors:  Haojun Xie; Hongmei Yao; Yating Huo; Ning Li; Yuanxiong Cheng
Journal:  Tumour Biol       Date:  2014-06-27

7.  Relationship between gene polymorphisms of two cytokine genes (TNF-α and IL-6) and occurring of lung cancers in the ethnic group Han of China.

Authors:  Jing Liang; Xiaolin Liu; Zhenqiang Bi; Beibei Yin; Junjuan Xiao; Hairong Liu; Yan Li
Journal:  Mol Biol Rep       Date:  2012-10-26       Impact factor: 2.316

8.  The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Yuki Moritou; Hiroaki Hagihara; Tetsuya Yasunaka; Kenji Kuwaki; Yasuhiro Miyake; Hideki Ohnishi; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Yoshiaki Iwasaki; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2012-08-07       Impact factor: 7.527

9.  Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea.

Authors:  Suk Pyo Shin; Nam Keun Kim; Ju Hwan Kim; Ju Ho Lee; Jung Oh Kim; Sung Hwan Cho; Hana Park; Mi Na Kim; Kyu Sung Rim; Seong Gyu Hwang
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

10.  TNF-α-308G/A polymorphisms and nasopharyngeal cancer risk: a meta-analysis.

Authors:  Li Xie; Xiao-Nan Liang; Yan Deng; Xue Qin; Shan Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-25       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.